LOLLIPOP (2002-03) N = 549 | POPS (1983) N = 679 | Effect of cohort (LOLLIPOP vs. POPS) | ||||||
---|---|---|---|---|---|---|---|---|
Model 1 | Model 2 | Model 3 | Model 4 | |||||
N | % | N | % | OR (CI 95%) | OR (CI 95%) | OR (CI 95%) | OR (CI 95%) | |
Morbidity | ||||||||
IVH grade III-IV | 18 | 3.6 | 47 | 9.3 | 0.36 (0.21–0.33)*** | 0.15 (0.04–0.50)** | 0.15 (0.04–0.55)** | 0.26 (0.06–1.12)(*) |
sepsis | 135 | 27.7 | 246 | 36.3 | 0.67 (0.52–0.87)** | 0.59 (0-40-0.86)** | 0.63 (0.42–0.96)* | 0.53 (0.32–0.88)* |
proven NEC | 12 | 2.3 | 11 | 1.6 | 1.42 (0.62–3.23) | 1.37 (0.38–5.04) | 1.56 (0.36–6.76) | 2.22 (0.45–11.10) |
apnea | 465 | 90.8 | 453 | 66.9 | 4.89 (3.48–6.87)*** | 6.02 (3.47–10.46)*** | 6.50 (3.65–11.57)*** | 10.52 (5.18–21.34)*** |
Care practices | ||||||||
Surfactant therapy | 191 | 34.8 | ||||||
mechanical ventilation | 291 | 55.7 | 302 | 47.0 | 1.42 (1.13-1-79)** | 1.22 (0.88–1.72) | 1.40 (0.97–2.03)(*) | 1.52 (0.96–2.42)(*) |
CPAP | 438 | 83.9 | 305 | 46.9 | 5.90 (4.46–7.80)*** | 6.99 (4.50-10.86)*** | 8.36 (5.22–13.37)*** | 7.88 (4.64–13.37)*** |
caffeine therapy | 452 | 89.3 | 402 | 64.1 | 4.68 (3.38–6.49)*** | 5.07 (3.07–8.36)*** | 5.62 (3.33–9.48)*** | 7.93 (4.26–14.77)*** |
postnatal corticosteroids | 28 | 5.5 | 49 | 7.2 | 0.76 (0.45–1.20) | 0.46 (0.20–1.07)(*) | 0.49 (0.20–1.18) | 0.54 (0.18–1.57) |
Median | Range | Median | Range | Model 1 IRR (CI 95%) | Model 2 IRR (CI 95%) | Model 3 IRR (CI 95%) | Model 4 IRR (CI 95%) | |
length of mechanical ventilation, days | 1 | 0–84 | 0 | 0–78 | 1.15 (0.91–1.46) | 1.10 (0.76–1.61) | 1.16 (0.76–1.78) | 0.92 (0.57–1.46) |
length of NICU stay, days | 16 | 0-143 | 38 | 0-380 | 0.48 (0.44–0.54)*** | 0.44 (0.38–0.51)*** | 0.41 (0.35–0.48)*** | 0.39 (0.33–0.46)*** |
length of hospital stay, days | 54 | 10–339 | 65 | 12–380 | 0.86 (0.82–0.90)*** | 0.86 (0.81–0.92)*** | 0.83 (0.78–0.90)*** | 0.89 (0.83–0.94)*** |